ETON NASDAQ
Credit Risk of going bust: lower than 62% of companies Debt: 1.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.17 (down 99.7%), Eton Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $29.0M against a stock market value of $1.46B.
Distance to default 6.46 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.4M (short-term plus half of long-term), stock volatility 66.1%; Altman Z 13.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Deer Park, IL 60010-7278
US
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Krempa David | S-Sale | 4,166 | $55.07 | 2026-10-06 |
| Krempa David | M-Exempt | 10,522 | — | 2026-10-02 |
| Krempa David | M-Exempt | 10,522 | — | 2026-10-02 |
| MAIER PAUL V | S-Sale | 36,387 | $58.64 | 2026-08-28 |
| MAIER PAUL V | S-Sale | 13,485 | $60.21 | 2026-08-28 |